Embecta Corp. (EMBC)
20.11
0.20 (1.00%)
At close: Jan 14, 2025, 3:59 PM
19.53
-2.88%
Pre-market Jan 15, 2025, 04:10 AM EST
undefined% (undefined)
| Bid | 8.14 |
| Market Cap | 1.17B |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | 1.34 |
| PE Ratio (ttm) | 15.01 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 24.49 |
| Volume | 268,124 |
| Avg. Volume (20D) | 394,008 |
| Open | 20.00 |
| Previous Close | 19.91 |
| Day's Range | 19.57 - 20.40 |
| 52-Week Range | 9.93 - 21.48 |
| Beta | undefined |
About EMBC
Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety devices, as well as digital applications to assist people with managing their diabetes. The company primarily sells its products to wholesalers and distributors in the United States and internationally. Embecta Corp. was founded in 1924 and...
Sector Healthcare
IPO Date Mar 22, 2022
Employees 2,200
Stock Exchange NASDAQ
Ticker Symbol EMBC
Website https://www.embecta.com
Analyst Forecast
According to 2 analyst ratings, the average rating for EMBC stock is "Buy." The 12-month stock price forecast is $19, which is a decrease of -5.52% from the latest price.
Buy 50.00%
Hold 0.00%
Sell 50.00%
Next Earnings Release
Embecta Corp. is scheduled to release its earnings on Feb 7, 2025,
before market opens.
Analysts project revenue of $261.31M, reflecting a -5.77% YoY shrinking and earnings per share of 0.47, making a -22.95% decrease YoY.
Analysts project revenue of $261.31M, reflecting a -5.77% YoY shrinking and earnings per share of 0.47, making a -22.95% decrease YoY.
1 month ago ·
Source
+29.77%
Embecta shares are trading higher after the compan...
Unlock content with
Pro Subscription
5 months ago ·
Source
+7.32%
Embecta shares are trading higher after the company reported better-than-expected Q3 revenue results and raised its FY24 adjusted EPS guidance.
